article thumbnail

Voxelotor for Sickle Cell Disease Recalled After Safety Concerns

HCPLive

Pfizer has announced the voluntary withdrawal of voxelotor in all markets after a report found the benefits do not outweigh the risks for sickle cell disease.

article thumbnail

Sickle Cell Disease Linked to Higher Risk of Retinal Vascular Occlusion

HCPLive

Patients with hemoglobin SS sickle cell disease type may experience a significantly elevated risk of retinal vascular occlusion.

article thumbnail

Social Determinants of Health Shape Pain Outcomes in Sickle Cell Disease

HCPLive

Education and employment, social and emotional functioning, and healthcare access are notable factors influencing pain in sickle cell disease.

article thumbnail

AND017 Receives FDA Orphan Drug Designation for Sickle Cell Disease

HCPLive

On October 25, 2024, Kind Pharmaceutical announced receipt of FDA Orphan Drug Designation for AND017 in the treatment of sickle cell disease.

article thumbnail

Safety of a potential new treatment to manage complications from sickle cell disease

Science Daily - Heart Disease

A drug approved to treat pulmonary arterial hypertension may be effective at managing hypertension and end-organ damage in patients with sickle cell disease, according to a new study.

article thumbnail

Study Addresses Menstrual Pain in Sickle Cell Disease, Role of Reproductive Health Specialists

HCPLive

Although more than half of female patients with sickle cell disease reported sickle cell pain associated with their menstrual cycles, only 12.5% had used ≥1 hormonal therapies within the past 3 months.

article thumbnail

Researchers identify safety of a potential new treatment to manage complications from sickle cell disease

Medical Xpress - Cardiology

A drug approved to treat pulmonary arterial hypertension may be effective at managing hypertension and end-organ damage in patients with sickle cell disease, according to a new study published in Lancet Haematology.